Reactome | MAOA inhibitors bind MAOA:FAD

MAOA inhibitors bind MAOA:FAD

Stable Identifier

R-HSA-9677917

Type

Reaction [binding]

Species

Homo sapiens

Compartment

cytosol, mitochondrial outer membrane

ReviewStatus

5/5

Locations in the PathwayBrowser

Expand all

General

SBML | | PDF

SVG | | PPTX | SBGN

Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Excess neurotransmitters are cleared from post-synaptic cells to prevent their overactivation. Dopamine and serotonin can be enzymatically degraded by monoamine oxidases A and B (MAOA, MAOB respectively). MAOA inhibitors (Fisar et al. 2010, Yoshida et al. 2004, Binda et al. 2008, Jagrat et al. 2014) are synthetic chemical agents that are used for depression (Chiuccariello et al. 2015, Fulton & Benfield 1996, Medvedev et al. 1998, Berlin et al. 1990) and Parkinson's (Mizuno et al. 2019).

Literature References

PubMed ID	Title	Journal	Year
1705137	Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects Hergueta, T, Zimmer, R, Robin, L, Thiede, HM, Berlin, I, Payan, C, Puech, AJ	Br J Clin Pharmacol	1990
31045589	Long-Term Selegiline Monotherapy for the Treatment of Early Parkinson Disease Kondo, T, Yamamoto, M, Origasa, H, Yanagisawa, N, Takahashi, R, Mizuno, Y, Hattori, N, Nomoto, M	Clin Neuropharmacol	2019
9564636	The influence of the antidepressant pirlindole and its dehydro-derivative on the activity of monoamine oxidase A and GABAA receptor binding Squires, RF, Medvedev, AE, Fedotova, OA, Saederup, E, Shvedov, VI, Chulkova, TM	J. Neural Transm. Suppl.	1998
18426226	Structural and mechanistic studies of arylalkylhydrazine inhibition of human monoamine oxidases A and B Wang, J, Li, M, Edmondson, DE, Mattevi, A, Hubálek, F, Binda, C	Biochemistry	2008
8875133	Moclobemide. An update of its pharmacological properties and therapeutic use Fulton, B, Benfield, P	Drugs	1996
21200377	Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers Raboch, J, Hroudová, J, Fisar, Z	Neuro Endocrinol Lett	2010
26316187	Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors Cooke, RG, Kish, SJ, Chiuccariello, L, Miler, L, Meyer, JH, Levitan, RD, Wilson, AA, Kolla, NJ, Houle, S, Rusjan, PM, Baker, GB	Int J Neuropsychopharmacol	2015
21680183	Pyrazoline based MAO inhibitors: synthesis, biological evaluation and SAR studies Sinha, BN, Ucar, G, Basu, A, Yabanoglu, S, Jagrat, M, Ercan, A, Jayaprakash, V, Behera, J, Sankaran, V	Bioorg. Med. Chem. Lett.	2011
15110846	Fluorinated phenylcyclopropylamines. Part 3: Inhibition of monoamine oxidase A and B Rosen, TC, Ye, S, Sloan, MJ, Kirk, KL, Yoshida, S, Haufe, G, Meyer, OG	Bioorg. Med. Chem.	2004